Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its U.S.-based point-of-care (POCare) services subsidiary, Morgenesis LLC, entered into a collaborative agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors.
Orgenesis has set up a partnership with Savicell Diagnostics to advance the development, QC testing and manufacturing of its cell and gene therapies.
GERMANTOWN, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc (ORGS). (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, has entered into a collaboration agreement (“Agreement”) with Savicell Diagnostics Ltd. (“Savicell”) to deploy Savicell’s patented ImmunoBiopsy™ immunometabolism platform with a goal of: (i) developing and validating diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies; (ii) developing new assays to enhance the potency of cell and gene therapies for use within its point-of-care (POCare) platform; and (iii) developing companion diagnostics for potential enhanced patient targeting of cell and gene therapies.
On Dec. 9, 2020, Orgenesis, a global biotech company focused on cell and gene therapies, and Cure Therapeutics, a developer of immuno-oncology and cell and gene therapies, announced that they have signed a joint venture agreement to advance the development, regulatory and governmental approval, and commercialization of point-of-care (POCare) production for both companies’ cell and gene therapies as well as immunotherapies.
The collaboration includes the development, commercialization, and supply of Orgenesis’ pipeline in South Korea and Japan and the development and commercialization of Cure Therapeutics’ pipeline on a global basis.
Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.
Biotech firm Orgenesis has signed a definitive merger agreement to acquire regenerative medicine company Koligo Therapeutics.
Orgenesis has struck a deal to acquire Koligo Therapeutics. The takeover will give Orgenesis control of an autologous cell therapy treatment for respiratory disease caused by COVID-19.
GERMANTOWN, Md., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Koligo Therapeutics, Inc. (“Koligo”), a regenerative medicine company, today announced that the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion before year-end (“Transaction”).
Orgenesis Inc., a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), announces it has entered into a preliminary, non-binding term sheet with Leidos (Leidos), a FORTUNE 500 science and technology leader, to develop and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the systemic treatment of patients suffering with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.